Chromatographic modeling for biopharmaceutical purification demands a detailed mechanistic understanding of pH dependent interactions among proteins, chromatographic ligands, buffering agents, and electrolytes. Foundational work by Pabst and Carta demonstrated that pH transients and gradients in weak ion exchangers can be effectively modeled by accounting for ligand titration. However, most existing models continue to emphasize the buffering capacity of the stationary phase while overlooking the substantial contributions of protein species. This simplification limits predictive accuracy under high-loading, process-relevant conditions where protein-associated buffering becomes significant. More recently, Hahn et al. extended Protein A chromatography models to include titration of the immobilized ligand, yet their approach excluded the buffering contribution of monoclonal antibodies and assumed a uniform pKa for all carboxyl groups on the Protein A ligand.
To address the limitations described in the above answer, the team proposes a new computational framework that integrates molecular-level characterization of the protein mixture with mechanistic process modeling to more comprehensively represent the coupled interactions among proteins, ligands, buffers, and salt electrolytes. This generalized framework is designed to be applicable across multiple chromatographic modes—including ion exchange (IEX), mixed-mode, hydroxyapatite, and Protein A systems—and applicable across a wide range of buffer and electrolyte conditions. Our overall project plan will lead to the development and validation of an easy-to-use, well-documented Python-based module for pH-dependent column simulations and model calibrations.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

University of Virginia
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
EMD Millipore Corporation
Federal Stakeholder: National Institute of Standards and Technology
Pfizer, Inc.
Sanofi